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 ORIGINAL ARTICLE 
 Adaptation requirements due to anatomical changes in free-breathing 
and deep-inspiration breath-hold for standard and dose-escalated 
radiotherapy of lung cancer patients 
 PATRIK  SIBOLT 1,2 ,  WIVIANN  OTTOSSON 2 ,  DAVID  SJ Ö STR Ö M 2 , 
 CHRISTINA  LARSEN 2  &  CLAUS F.  BEHRENS 2 
 1 Center for Nuclear Technologies, Technical University of Denmark, DTU Ris ø Campus, Roskilde, Denmark and 
 2 Department of Oncology, Radiotherapy Research Unit, Herlev Hospital, University of Copenhagen, Herlev, 
Denmark 
 ABSTRACT 
 Background. Radiotherapy of lung cancer patients is subject to uncertainties related to heterogeneities, anatomical 
changes and breathing motion. Use of deep-inspiration breath-hold (DIBH) can reduce the treated volume, potentially 
enabling dose-escalated (DE) treatments. This study was designed to investigate the need for adaptation due to ana-
tomical changes, for both standard (ST) and DE plans in free-breathing (FB) and DIBH. 
 Material and methods. The effect of tumor shrinkage (TS), pleural effusion (PE) and atelectasis was investigated 
for patients and for a CIRS thorax phantom. Sixteen patients were computed tomography (CT) imaged both in FB and 
DIBH. Anatomical changes were simulated by CT information editing and re-calculations, of both ST and DE plans, in 
the treatment planning system. PE was systematically simulated by adding fl uid in the dorsal region of the lung and TS 
by reduction of the tumor volume. 
 Results. Phantom simulations resulted in maximum deviations in mean dose to the GTV-T (  D  GTV-T ) of   1% for 
3 cm PE and centrally located tumor, and    3% for TS from 5 cm to 1 cm diameter for an anterior tumor location. For 
the majority of the patients, simulated PE resulted in a decreasing   D  GTV-T with increasing amount of fl uid and 
increasing   D  GTV-T for decreasing tumor volume. Maximum change in   D  GTV-T of -3% (3 cm PE in FB for both 
ST and DE plans) and    10% (2 cm TS in FB for DE plan) was observed. Large atelectasis reduction increased the 
  D  GTV-T with 2% for FB and had no effect for DIBH. 
 Conclusion. Phantom simulations provided potential adaptation action levels for PE and TS. For the more complex 
patient geometry, individual assessment of the dosimetric impact is recommended for both ST and DE plans in DIBH 
as well as in FB. However, DIBH was found to be superior over FB for DE plans, regarding robustness of   D  GTV-T 
to TS. 
 Lung cancer is one of the most common cancer dis-
eases worldwide [1 – 3]. Unfortunately lung cancer 
patients also suffer from a high mortality rate and the 
local control for patients undergoing radiotherapy as 
a part of their treatment is poor. Escalating the radi-
ation dose to the tumor could lead to an increased 
cure rate [4]. Even if this statement is debatable in 
the light of the results of the RTOG0617 study [5,6], 
the idea of dose-escalated (DE) radiotherapy of lung 
cancer patients is generally supported and emerging 
dose escalation studies, having higher focus on qual-
ity assurance and keeping the dose to normal tissues 
as low as for ST treatments, should proceed [7]. 
 In radiotherapy of lung cancer patients, extensive 
margins are added to the tumor volume in order to 
account for uncertainties related to baseline shifts, 
delineation, organ motion and respiration [8,9]. This 
results in large irradiated volumes of adjacent normal 
tissue, limiting escalation of the dose to the tumor. 
Setup margins in the thorax region can be reduced 
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by moving from bony match on the spine towards 
direct match on the soft tissue of the lung tumor 
[10]. Further margin reduction is conceivable by 
synchronizing the radiation delivery with tumor 
motion [11]. Use of deep-inspiration breath-hold 
(DIBH) reduces the tumor motion and can poten-
tially enable DE treatments of lung cancer patients, 
without increasing the severe radiation-induced side 
effects of organs at risk (OARs) [12,13]. 
 Radiotherapy of lung cancer patients is, however, 
also subject to uncertainties related to heterogene-
ities and anatomical changes. As margins are mini-
mized and dose to the tumor is conformed and 
escalated, adaptation of the treatment plan due to 
anatomical changes could become more crucial. Pre-
vious studies demonstrate that changes in dose due 
to anatomical changes have the largest effect on the 
delivered dose to the tumor [14]. One reason being 
the lung density alteration that arises with the appear-
ance of anatomical changes, such as atelectasis, 
pneumonitis, pleural effusion (PE) and tumor shrink-
age (TS). While previous studies have investigated 
the effect of anatomical changes and need for adap-
tive strategies in ST fractionated treatment of lung 
cancer patients in free-breathing (FB) [14,15], there 
is a lack of studies investigating the potential need 
for adaptation in DE treatment of lung cancer 
patients in DIBH. 
 This study is designed to investigate the need for 
adaptation due to lung density alteration as a result 
of PE, TS or atelectasis, for both ST and DE plans 
in FB and DIBH. 
 Material and methods 
 Data and treatment preparations 
 In order to perform simulations in a reproducible, 
well defi ned geometry, a three-dimensional com-
puted tomography (3DCT) of the CIRS thorax 
phantom (CIRS Inc., Norfolk, VA, USA) was 
acquired. Spherical gross tumor volumes (GTV-Ts) 
with a diameter of 5 cm were delineated in the ante-
rior (A), central (C) and posterior (P) part of the left 
lung insert, and given Hounsfi eld units (HUs) cor-
responding to water. OARs, clinical target volumes 
(CTV-Ts) and planning target volumes (PTV-Ts) 
were defi ned and ST plans were produced, for all 
situations. 
 Furthermore, 16 locally advanced non-small cell 
lung cancer (NSCLC) patients scheduled for cura-
tive radiotherapy, between December 2012 and July 
2014, were enrolled. One 4DCT in FB and one 
3DCT in DIBH, both with intravenous contrast, 
were acquired prior to, in the middle of and after the 
course of treatment. Target volumes and OARs, both 
in FB and DIBH, were delineated separately on each 
CT dataset by an oncologist in a treatment planning 
system (TPS) (Eclipse, Varian Medical Systems, Palo 
Alto, CA, USA) [10]. Dose calculations of ST (uti-
lized for treatment on Varian 2300 iX linear accel-
erators [16]) and DE volumetric modulated arc 
therapy (VMAT) plans were carried out in the same 
TPS, using the AAA calculation algorithm [17]. 
 Additional information regarding the clinical pro-
tocol, patient characteristics, scanning procedures, 
delineations and treatment planning is provided in 
the Supplementary Appendix (available online at: 
http://informahealthcare.com/doi/abs/10.3109/0284
186X.2015.1062543). 
 Pleural effusion 
 The dosimetric effect of PE was simulated for ST 
plans in FB and three different tumor locations in 
the CIRS thorax phantom (Figure 1a). Simulations 
of PE in patients were carried out on the pre-treat-
ment CT scans by adding 1, 2 or 3 cm fl uid in the 
dorsal region of the lung (patient in supine position) 
(Figure 1b), resulting in three new image sets per 
patient and scanning technique. Simulations were 
carried out by altering the HUs in the PE region to 
correspond to water. PE was realistically simulated 
in the sense that no adjustment was made to the fact 
that the posterior wall of the lung was not in the same 
vertical position for the entire longitudinal extension 
of the patient. This implies that the amount of fl uid 
varied over the longitudinal length of the lung, 
including the tumor region and depending on the 
 Figure 1. Examples of simulated anatomical changes: a) 3 cm 
pleural effusion for the centrally located tumor in the CIRS thorax 
phantom, b) 3 cm pleural effusion in a patient, c) tumor shrinkage 
in the form of 1 cm radius reduction in a patient, and d) large 
atelectasis disappearance between pre-treatment (upper) and 
post-treatment (lower) CT. Colors available online. 
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4DCT and DIBH 3DCT were rigidly registered 
to corresponding CTs acquired post-treatment, 
according to a soft tissue tumor position verifi cation 
procedure currently in practice at our clinic. OARs 
and target volumes were re-delineated on the post-
treatment CTs. The dosimetric effect of atelectasis 
was investigated by re-calculation of the original 
ST and DE plans in FB and DIBH on the post-
treatment CT scans, preserving the MU from the 
original plans. 
 Statistical analysis 
 Statistical analysis was carried out in MATLAB, 
including the Statistics Toolbox 8.3 (R2013b), (The 
MathWorks, Natick, MA, USA). The aim was to dis-
cover potentially statistically signifi cant differences 
between the impacts of anatomical changes in DIBH 
and FB as well as between ST and DE plans. Bonfer-
roni corrected two-sided Wilcoxon signed rank tests 
were applied to test the medians of the data, for each 
level of anatomical change. Results were considered 
statistically signifi cant at p    0.004 and p    0.003, for 
PE and TS, respectively. 
 Results 
 Pleural effusion 
 Phantom simulations resulted in a reduction of 
the mean dose to the GTV-T (  D  GTV-T ) with 
increasing amount of PE for all tumor positions 
(Figure 2), with a maximum decrease of 1.3% 
for the centrally located tumor. For anteriorly and 
patients ’ lung geometry as well as tumor location. 
Original ST and DE plans were re-calculated on 
the new image sets, preserving the original monitor 
units (MU). 
 Tumor shrinkage 
 TS was simulated for ST plans and the three tumor 
locations in the CIRS thorax phantom. Simulations 
of TS in patients were carried out on the pre-treat-
ment CT scans by reductions of the GTV-T radius 
of the tumor regions adjacent to the lung, both in 
FB and DIBH (Figure 1c). Thus, parts of tumor 
extending into the mediastinum, thoracic wall or 
adjacent to the spinal cord were not reduced. TS was 
simulated stepwise from a 0.5 cm to a 2.0 cm reduc-
tion, with a step size of 0.5 cm, by altering HUs in 
the subtracted volume to correspond to the sur-
rounding lung tissue, resulting in four new image sets 
per patient and scanning technique. New CTV-Ts 
and PTV-Ts were re-generated in each new image 
set. One patient was excluded due to atelectasis at 
the time of pre-treatment CT. Furthermore, not all 
patients had GTV-Ts large enough to enable shrink-
age in all steps. Original ST and DE plans were re-
calculated on the new image sets, preserving the MU 
from the original plans. 
 Atelectasis 
 One patient had atelectasis enclosing the GTV-T at 
the planning stage (Figure 1d upper). The atelectasis 
regressed and fi nally disappeared during the course 
of treatment (Figure 1d lower). Pre-treatment FB 
 Figure 2. Impact of pleural effusion (upper row) and tumor shrinkage (lower row) on Dmax to the spinal cord as well as   D  GTV-T  
  D  CTV-T and   D  PTV-T for simulations carried out in a CIRS dynamic thorax phantom (locations: A, anterior; C, central; P, 
posterior). 
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centrally located tumors, this trend was also visible 
for the mean dose to the CTV-T (  D  CTV-T ) and 
the mean dose to the PTV-T (  D  PTV-T ). For the 
posteriorly positioned tumor only a slight decrease 
of the   D  CTV-T was observed, while the   D  PTV-T 
increased. 
 For the majority of the patients, simulated PE 
resulted in decreasing   D  GTV-T with increasing PE 
(Figure 3). Up to 2.8% decrease was observed for 
3 cm PE in FB for both ST and DE plans (Patient 6). 
For the largest amount of PE, median decrease in 
  D  GTV-T among patients was similar in DIBH 
(  0.3% for both ST [  2.4%; 0.7%] and DE [  2.3%; 
0.6%] plans) and in FB (  0.3% [  2.8%; 0.5%] for 
ST and   0.4% [  2.8; 0.6] for DE plans). Some 
patients (9, 12 and 15) presented no change in 
  D  GTV-T with changing amount of PE, and 
for a few patients (7, 10 and 13)   D  GTV-T even 
increased with increasing amount of PE (Figure 3). 
 The Bonferroni corrected two-sided Wilcoxon 
signed rank test resulted in no statistically signifi cant 
differences, when considering the effect of PE on 
  D  GTV-T , between FB and DIBH or between ST 
and DE plans. 
 Additional results for the effect of PE on the 
maximum dose (D max ) to the spinal cord is provided 
in the Supplementary Appendix available online 
at: http://informahealthcare.com/doi/abs/10.3109/
0284186X.2015.1062543. 
 Tumor shrinkage 
 Phantom simulations of TS resulted in increasing 
  D  GTV-T ,   D  CTV-T and   D  PTV-T with decreas-
ing GTV-T, for all tumor locations (Figure 2). TS had 
less effect on the   D  CTV-T than on the   D  GTV-T , 
and even smaller impact on the   D  PTV-T . A maxi-
mum increase of the   D  GTV-T by 3.1% was observed 
for the anteriorly located tumor. A difference    1% in 
mean dose was reached at a radius reduction of 1 cm 
for the GTV-T, and 1.5 cm reduction for the CTV-T 
and PTV-T. 
 Similar to phantom simulations, increasing 
  D  GTV-T for decreasing tumor volume was observed 
for the majority of the patients, regardless of motion 
management technique and fraction dose (Figure 4), 
with a maximum increase of 10.4% (DE plan in FB 
for Patient 3). For the largest amount of TS, median 
increase in   D  GTV-T among patients was smaller in 
DIBH (2.6% [0.8%; 4.1%] for ST and 2.5% [  3.6%; 
6.9%] for DE plans) than in FB (2.6% [0.6%; 4.7%] 
for ST and 5.1% ([.6%; 10.4%] for DE plans). In a 
few cases   D  GTV-T decreased with decreasing tumor 
volume (DE plan in DIBH for Patients 6, 9 and 11, 
and ST plan in DIBH for Patients 5 and 9). 
 For TS, Bonferroni corrected Wilcoxon signed 
rank testing on the percentage difference in 
  D  GTV-T , resulted in statistically signifi cant differ-
ences, at 0.5 cm radius reduction of the GTV-T, 
between ST and DE plans for both DIBH (p    0.001; 
median increase of 0.4% [  0.4%; 1.1%] for ST and 
1.1% [  0.2%; 6.4%] for DE plans) and FB 
(p    0.001; median increase of 0.5% [0.0%; 0.7%] 
for ST and 1.7% [0.0%; 3.8%] for DE plans). 
However, for 1 cm radius reduction, statistical sig-
nifi cance was only observed for corresponding differ-
ences in FB (p    0.002; median increase of 1.1% 
[0.4%; 1.8%] for ST and 3.4% [0.6%; 5.5%] for DE 
plans). For all other cases, no statistically signifi cant 
differences were observed. 
 Figure 3. Impact of pleural effusion on   D  GTV-T for all 16 patients and combinations of scanning technique and fractionation. 
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 Spinal cord results for TS are provided in the 
Supplementary Appendix available online at: http://
informahealthcare.com/doi/abs/10.3109/0284186X.
2015.1062543. 
 Atelectasis 
 In addition to atelectasis reduction during the course 
of treatment for Patient 1 (Figure 1d), the total 
GTV-T decreased by 43.8% and 24.8% for FB and 
DIBH, respectively. These changes increased the 
mean dose of the total GTV-T for the ST plan with 
2.4% in FB and 0.2% in DIBH. Corresponding 
numbers for the DE plans were an increase of 1.9% 
and a decrease of 5.2% for FB and DIBH, respec-
tively. A larger decrease in minimum dose to the tar-
get was observed in DIBH (45.3% for ST and 53.8% 
for DE plan) than in FB (0.1% for ST and 3.5% for 
DE plan). Spinal cord results are available in the 
Supplementary Appendix available online at: http://
informahealthcare.com/doi/abs/10.3109/0284186X.
2015.1062543. 
 Discussion 
 The dosimetric impacts of PE, TS and atelectasis on 
VMAT treatment of NSCLC patients were investi-
gated, both for ST and DE treatments in FB as well 
as in DIBH. For the clinically realistic ranges of 
PE and TS considered in the current study, 
both phantom (Figure 2) and patient simulations 
(Figures 3 and 4, Supplementary Figures 1 and 2, 
available online at: http://informahealthcare.com/
doi/abs/10.3109/0284186X.2015.1062543) indicate 
that TS have larger dosimetric impact than PE, when 
considering both targets and the spinal cord. 
 For the majority of the patients a decreasing 
  D  GTV-T was observed for increasing amount of 
PE, while spinal cord D max increased. This general 
decrease in target dose is in concordance with previ-
ous studies [14,15]. The exceptions from this are in 
most cases due to the location of the tumor. A pos-
teriorly positioned tumor will in some cases get sur-
rounded by fl uid during PE, resulting in a build-up 
effect that is greater than the attenuating effect. This 
is, e.g. indicated by the increase in   D  CTV-T and 
  D  PTV-T of the posteriorly located tumor in the 
phantom simulations. The few patient cases where 
almost no change in   D  GTV-T was present during 
PE simulations could be explained by the tumor 
being located in the superior region of the lung where 
no PE was present (located outside the photon 
beam). The variation in tumor shapes, sizes and loca-
tions of the patient cohort, do also to some extent 
explain the spread in the resulting deviations from 
the original   D  GTV-T . No apparent difference was 
observed, when considering robustness to PE, in 
using DIBH or FB, neither for ST or DE plans, also 
supported by the lack of statistically signifi cant dif-
ferences, when considering   D  GTV-T . Any conclu-
sion regarding potential advantage, in terms of 
robustness to PE, in utilizing DIBH or FB when 
moving towards DE plans, would require larger data 
sets to strengthen the statistics. 
 TS mostly resulted in an increase in   D  GTV-T 
for decreasing tumor volume, complying with the 
fi nding of Schmidt et  al. [14], who for ST plans 
observed increases of   D  CTV-T of up to 4.0% when 
TS occurred. Similarly, also spinal cord D max 
 Figure 4. Impact of tumor shrinkage on   D  GTV-T for all 16 patients and combinations of scanning technique and fractionation. 
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increased with decreasing tumor volume for the 
majority of the patients. These effects were further-
more observed when simulating TS in a phantom, 
regardless of tumor location. However, phantom 
simulations were carried out by isotropic reduction 
of the tumor radius, while TS in patients was carried 
out by only altering the GTV-T adjacent to lung tis-
sue. Furthermore, the patient population consisted 
of a variation of original GTV-T volumes and loca-
tions, affecting the tumor reductions and contribut-
ing to the observed inter-patient variation, regarding 
the differences in   D  GTV-T . Original tumor volume 
can be of importance, as, e.g. reduction of already 
small tumors surrounded by lung tissue will increase 
the effect of lack of charged particle equilibrium. 
However, a larger patient cohort is necessary in order 
to make a statistically signifi cant statement regarding 
this dependency. Alternatively, actual anatomical 
changes appearing during the course of treatment 
could be utilized, as in previous studies [14,15]. 
Nevertheless, statistically signifi cant differences in 
  D  GTV-T were observed between ST and DE plans 
for 0.5 cm and 1 cm simulated TS when treating in 
FB. For DIBH, statistical signifi cance between ST 
and DE plans was only observed for a 0.5 cm reduc-
tion. This indicates that: 1) DE plans are potentially 
inferior to ST plans in terms of robustness to TS, 
when considering   D  GTV-T ; and 2) DIBH poten-
tially can reduce the impact of TS for DE treatments. 
This could be explained by the smaller original 
GTV-T volume when utilizing DIBH, compared to 
FB [13]. 
 The low variation in the effect on the   D  GTV-T 
for TS    1 cm radius reduction could explain the 
statistically signifi cant differences observed when 
comparing ST and DE plans. The same variation 
generally increases with increasing anatomical 
changes and was observed to be larger in com-
parisons between motion management techniques 
than fractionation schemes. However, for both PE 
and TS, statistical analysis of the difference between 
DIBH and FB resulted in decreasing p-values with 
increasing anatomical changes, even if never reach-
ing statistical signifi cance, and smaller p-values 
were generally observed for DE than for ST plans. 
The median deviations in   D  GTV-T for the 
largest anatomical changes indicate that DIBH has 
a potential superiority when considering TS 
(Figure 4), while similar responses to PE were 
observed (Figure 3). 
 When considering atelectasis, varying results 
regarding changes in doses to the GTV were observed 
amongst the different scanning techniques and frac-
tionations in the one patient where atelectasis disap-
peared during treatment. However, GTV-T also 
decreased during the course of treatment (larger 
decrease observed in FB than in DIBH). Together 
with registration and delineation uncertainties, this 
could explain the dosimetric variations observed. 
 In general, the present study indicates a potential 
benefi t in utilizing DIBH instead of FB during DE 
radiotherapy of NSCLC patients, regarding robust-
ness to anatomical changes. However, it does not 
take into account any differences in inter- or intra-
fractional uncertainties during setup and delivery of 
VMAT treatment in DIBH or FB. Furthermore, as 
positron emission tomography (PET) is necessary 
for DE treatment, adaption of treatment plans may 
require a new PET [18]. In addition to the PET 
signal being sensitive to tissue response after radio-
therapy, performing a reproducible PET at the stage 
of adaption may be a challenge, and is not trivial, as 
the PET-active volume may be deformed, systemati-
cally moved, or new PET-active volumes may be 
present [19]. The patients enrolled in the current 
study were only PET imaged in FB. Thus, in order 
to minimize the bias between DE plans in FB and 
DIBH, the dose escalation was applied to the entire 
GTV-T volume in both image sets. The impact of 
this on the results in the current study is considered 
small. 
 Standard action levels are diffi cult to defi ne. If 
1% change in   D  GTV-T would be considered as the 
action level required, phantom data indicate that 
action should be taken for PE of    3 cm thickness 
and TS of    1 cm radius reduction. This was not con-
fi rmed by the patient data, where a larger variation 
in changes with PE and TS was observed. However, 
PE results are in concordance with M ø ller et  al. [15], 
who observed PE for 13 of 163 studied patients and 
deviations in   D  PTV-T    1% in four cases with    2 
cm PE. 
 Randomly occurring anatomical changes of the 
sort presented in this study can most likely not be 
accounted for by extending margins. Thus, an 
adaptive strategy is necessary where the changes 
during the course of treatment are monitored for 
each patient individually. M ø ller et  al. [15] have 
presented results of a random pattern in the 
appearance and disappearance of anatomical 
changes supporting this statement. Rapid adaption 
to anatomical changes (e.g. daily adaptive plan 
selection) has previously been proven benefi cial for 
normal tissue sparing in sites, such as bladder 
[20]. A similar approach, together with the reduc-
tion in treatment volume from utilizing DIBH, is 
appealing for sparing normal tissue in lung cancer 
radiotherapy. Similarly to the current study, an 
approach of density alterations, based on daily 
cone beam computed tomography (CBCT) image 
information, could be utilized in order to alter the 
original CT, on which re-calculation of the original 
D
ow
nl
oa
de
d 
by
 [P
atr
ik 
Si
bo
lt]
 at
 02
:46
 16
 A
ug
us
t 2
01
5 
  Adaptive radiotherapy of NSCLC patients; FB vs. DIBH  7
treatment plan could be carried out. Preferably, 
deformable image registration would be utilized in 
order to transfer anatomical information from the 
CBCT to the original CT image. However, there 
are known issues required to be solved before hav-
ing a reliable deformable image registration tool 
effective for evaluating lung cancer radiotherapy 
over the course of treatment [21]. It should be 
mentioned that there are limitations in the AAA 
calculation algorithm when calculating dose in 
heterogeneous situations [22 – 24], and Monte 
Carlo simulations could potentially render differ-
ent results [25]. 
 In conclusion, phantom simulations have pro-
vided information about potential action levels for 
when adaptation to appearance of either PE or TS is 
required. However, for the more complex patient 
geometry, also tumor volume and location needs to 
be taken into consideration. Individual assessment of 
the dosimetric impact should rather be carried out 
instead of applying standard action levels. This is the 
recommendation for both ST and DE treatment 
plans in DIBH as well as in FB, even if the current 
study suggests a potential superiority in DIBH, 
regarding the robustness in   D  GTV-T to anatomical 
changes in DE treatment. 
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